News|Videos|November 16, 2026

What Pharmacists Should Know About Shifting Peptide Policy

With patients buying gray-market peptides, HHS’s draft policy aims to reunite prescribers, patients, and pharmacists around these emerging products.

As the comment period closes on a Department of Health and Human Services (HHS) draft policy that would let 503A pharmacies compound 6 unapproved peptides without federal enforcement, experts are urging pharmacy leaders to wait for the final version of the policy from FDA.

“I think it’s important to note that the policy is a draft policy and it has an open comment period that’s about to end. Anytime you have an opportunity for comments on a policy, [that] means that policy could have some changes that are made to it. It’s not guaranteed,” Matt Martin, PharmD, BCSCP, vice president of clinical services at PCCA, told Drug Topics.

As HHS moves fast on bringing peptide distribution to life across the pharmaceutical supply chain, pharmacists and their patients are raising questions, concerns, and a sheer curiosity for a therapeutic intervention similar to the weight-loss medications that have flooded medication discussions in recent history.

In this week’s episode of the Over the Counter podcast, Martin joins to help the Drug Topics audience better understand what’s happening with peptides. More importantly, he’ll help pharmacy leaders make the proper calls now for how they wish to approach the peptide landscape, as regulatory and government bodies like FDA and HHS make decisions in real time.

READ MORE: Q&A: Emerging Compounded Therapies Demand Pharmacist’s Clinical Judgment | NCPA 2026

Navigating Gray-Market Realities and Regulated Access Pathways

The peptide landscape has been complex for years because consumers frequently seek out these therapies across social media platforms and online venues where products are sold under research-use-only labels.

According to Martin, pharmacists and prescribers have faced a relentless stream of inquiries from patients trying to obtain these compounds outside conventional health care channels. HHS framed its draft policy around creating a regulated environment that reestablishes the traditional care triad between the patient, prescriber, and pharmacist.1

This interim framework covers 6 specific peptides including BPC-157, TB-500, KPV, Semax, MOTS-c, and Epitalon, allowing state-licensed 503A pharmacies to compound them under designated quality standards and route limitations without facing federal enforcement action. Industry proponents and telehealth platforms view this policy shift as an opportunity to expand legitimate patient access while steering consumers away from unverified online sellers.1-3

Scientific Opposition and Professional Safety Warnings

Despite federal efforts to expand regulated access, substantial pushback has emerged from scientific staff at the FDA who warn that bypassing formal approval processes carries public health risks. Agency reviewers previously concluded that none of the nominated peptides met statutory criteria for inclusion on the official bulk drug list due to limited human clinical trial data and uncertainties surrounding product characterization.2,3

Major professional societies have echoed these scientific concerns.4,5

The American Medical Association (AMA) formally adopted policy urging federal health authorities to rescind directives that ease compounding restrictions on unapproved synthetic peptides. AMA leaders warned that compounding these substances without sufficient proof of safety and efficacy exposes patients to serious, preventable harm.4

Similarly, the American Pharmacists Association (APhA) submitted formal comments emphasizing that patient safety and rigorous science must guide federal reviews. Brigid Groves, PharmD, MS, APhA’s vice president of professional affairs, noted that existing evidence remains insufficient for clinicians to confidently counsel patients regarding long-term safety, drug interactions, and therapeutic outcomes.5

Operational Compliance and Strategy for Pharmacy Leaders

Given that the federal policy remains in draft form, Martin advises pharmacy leaders to exercise caution and monitor regulatory developments before committing to full-scale operational changes. Because public feedback could alter specific provisions, current requirements may shift before the FDA issues its finalized rulemaking.2

Pharmacies considering entry into peptide compounding must verify that bulk active ingredients originate strictly from registered facilities complying with current good manufacturing practices and providing thorough certificates of analysis. Compounders must also maintain documentation confirming adequate absorption for oral formulations, adhere to mandatory adverse event reporting through federal MedWatch channels, and apply required product labeling.1-3

State boards of pharmacy will ultimately determine local enforcement standards, requiring pharmacy managers to evaluate both state and federal rules prior to dispensing.1,2

“What you think is the requirement today may not be the requirement when this policy changes,” concluded Martin. “Maybe it doesn’t change at all; we don’t know.”

Stay tuned for more from our discussion with Martin.

READ MORE: Compounding Resource Center

REFERENCES
1. Nowosielski B, Lee D, Morgan L. HHS lets pharmacies compound peptides as FDA writes official rule. Drug Topics. October 29, 2026. Accessed November 13, 2026. https://www.drugtopics.com/view/hhs-lets-pharmacies-compound-peptides-as-fda-writes-official-rule
2. Billingsley A, Woodcock S. Peptide watch: the latest news and FDA developments on peptides. October 28, 2026. Accessed November 13, 2026. https://www.goodrx.com/health-topic/peptides/what-peptides-are-fda-approved
3. Perrone M. RFK Jr. eases access to unproven peptides despite opposition from FDA scientists. ClickOrlando. October 28, 2026. Accessed November 13, 2026. https://www.clickorlando.com/business/2026/10/28/fda-scientists-opposed-the-trump-administrations-effort-to-ease-peptides-access/
4. AMA adopts new policies to protect patients and strengthen public health. American Medical Association. News Release. November 9, 2026. Accessed November 13, 2026. https://www.ama-assn.org/press-center/ama-press-releases/ama-adopts-new-policies-protect-patients-and-strengthen-public
5. American Pharmacists Association urges FDA to put patient safety first in peptide review. Practical Dermatology. July 17, 2026. Accessed November 13, 2026. https://practicaldermatology.com/news/apha-urges-fda-to-put-patient-safety-first-in-peptide-review/2487836/

Related to this article